Analgesic effects of nerve growth factor‐directed monoclonal antibody on diabetic neuralgia in an animal model

Analgesic effects of nerve growth factor‐directed monoclonal antibody on diabetic neuralgia in an animal model

Current treatment options for diabetic neuralgia are limited and unsatisfactory. Tanezumab, a monoclonal antibody that blocks nerve growth factor (NGF) signaling, has been shown to be effective in relieving the clinical symptoms of osteoarthritis pain, chronic low back pain, cancer pain induced by b...

Full description

Bibliographic Details
Main Authors: Xingchen Dong, Huanhuan Li, Min Pei, Jie Tan, Ganjun Chen, Santai Li, Zuobin Xie, Qi Wang, Guifeng Wang, Yi‐Li Chen, Chunhe Wang
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:FEBS Open Bio
Subjects:
diabetic neuralgia
neuropathic pain
nerve growth factor
monoclonal antibody
analgesia
Online Access:https://doi.org/10.1002/2211-5463.13410

Internet

https://doi.org/10.1002/2211-5463.13410

Similar Items